Clinical Trials Browser

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT05269381 2026-03-12

PNeoVCA

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinosarcoma, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

Clinical Trials

I-SPY

PNeoVCA

A Study of Tetrathiomolybdate (TM) Plus Capecitabine

TELESCOPE

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

PRELUDE

A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer

Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer

Cancer Immunotherapeutic (PCI) Strategy in Triple Negative Breast Cancer Patients

Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer

BRINK

ASTEROID

ToPCourT

Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy

Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer

Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy

INTEGRAL

Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients

Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype

ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC

Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer

Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)

High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer

ADAPT-TN-III

CAPPA

ETNA

Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC

NeoCARD

NeoSTAR

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

NeoTRACT

PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer

NeoADAPT

ADAPT-TN-IV

NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC

Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca

Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation

OPT-PEMBRO

ComPACT

NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours

A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer

Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer

Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer

PERSEVERE

A Study of Pembrolizumab and Cryoablation in People With Breast Cancer

Breast Cancer Study of Preoperative Pembrolizumab + Radiation

INSPIRE

Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer

Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer

Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer